Malignancy in Myelofibrosis Patients Receiving Ruxolitinib Therapy

A Restrospective Study of Secondary Malignancies in Myelofibrosis Patients Receiving Ruxolitinib Therapy Myelofibrosis (MF) is a chronic, rare, and often fatal type of blood cancer characterized by a progressive replacement of bone marrow with fibrous scar tissue. This type of myeloproliferative neoplasm (MPN) leads to progressive spleen enlargement, systemic symptoms such

Study on the Ocular involvement in metastatic and systemic malignancies

Ocular Involvement of Systemic Malignancies Systemic malignancies affecting the eye often involve the choroid or the orbital area of the eye, leading to different ocular manifestations. Ocular malignancies are relatively rare compared to malignancies of other parts of the human body. The American Cancer Society estimates there will be about 3,300 new eye cancer

Exploring Gene Profiles in Small Bowel Adenocarcinoma

Exploring Gene Profiles in Small Bowel Adenocarcinoma Small bowel adenocarcinoma (SBA) is one of the rarest tumors found in patients. In fact, SBA only represents about 1-3% of all gastrointestinal malignancies. Due to its rarity, genomic analyses and prognostic biomarkers are limited. About 55-82% of small bowel adenocarcinomas can be found in

Oncology-Specific Opioid Risk Calculator in Cancer Survivors

Oncology-Specific Opioid Risk Calculator in Cancer Survivors Despite the great progress made in terms of diagnosis and treatment, cancer is still a dreaded diagnosis. This devastating disease has a sweeping reach. The International Agency for Research on Cancer (IARC) figures for global cancer burden estimates were 19.3 million new cases and

Quality of Life in Adolescent Cancer Survivors

A Study of the Quality of Life Among Adolescent and Young Adult Cancer Survivors Every year, around 8,000 Canadian adolescent and young adults (AYA) are diagnosed with cancer , and about 5% of all cancer diagnoses in the United States are in this population. The survival rates are high in this

Malignancy in Myelofibrosis Patients Receiving Ruxolitinib Therapy